S3 Fig. Western Blots analysis, part 1: Western blot analysis of mesenteric arteries submitted to normal flow (NF) or to high flow (HF) isolated of rats treated with resveratrol 5 (R5.0) or 37.5mg/kg per day (R37.5) or with the solvent (DMSO) or nothing (Cont.).

The following proteins were analyzed: endothelial NO syntase (eNOS), cyclooxygenase-2 (COX2), p47phox, Cu/ZnSOD, cyclooxygenase-1 (COX1), Cytochrome C Oxidase IV (Cyto C) and beta actin (βActin).
**S3 Fig. Western Blots analysis, part 2:** Western blot analysis of mesenteric arteries submitted to normal flow (NF) or to high flow (HF) isolated of rats treated with resveratrol 5 (R5.0) or 37.5mg/kg per day (R37.5) or with the solvent (DMSO) or nothing (Cont.).

The following proteins were analyzed: endothelial NO syntase (eNOS), cyclooxygenase-2 (COX2), p47phox, Cu/ZnSOD, cyclooxygenase-1 (COX1), Cytochrome C Oxidase IV (Cyto C) and beta actin (βActin).
S3 Fig. Western Blots analysis, part 3: Western blot analysis of mesenteric arteries submitted to normal flow (NF) or to high flow (HF) isolated of rats treated with resveratrol 5 (R5.0) or 37.5mg/kg per day (R37.5) or with the solvent (DMSO) or nothing (Cont.).

The following proteins were analyzed: Sir2uin-1 (Sirt-1), phospho-ERK1/2 (ph-ERK), ERK1/2 and beta actin (βactin)
S3 Fig. **Western Blots analysis, part 4:** Western blot analysis of mesenteric arteries submitted to normal flow (NF) or to high flow (HF) isolated of rats treated with resveratrol 5 (R5.0) or 37.5mg/kg per day (R37.5) or with the solvent (DMSO) or nothing (Cont.).

The following proteins were analyzed: Sirtuin-1 (Sirt-1), phospho-ERK1/2 (ph-ERK), ERK1/2 and beta actin (βactin).